Clinical trial
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary…
NCT00301756 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00301756 |
|---|---|
| Title | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors |
| Official title | A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Ovarian Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Ovarian Cancer |
| Intervention type | Drug, Other |
| Interventions | Belinostat, Laboratory Biomarker Analysis |
| Enrollment | 32 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Dec 1, 2012 |
| First posted | Mar 13, 2006 |
| Last update posted | Aug 20, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: